Protocol Ledger

NCT05798663 · Phase II · ACTIVE NOT RECRUITING

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Interventional Phase II clinical trial protocol NCT05798663 sponsored by Alliance Foundation Trials in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-07 Enrollment: 178 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05798663
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)178 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05798663
Protocol FieldVerified Registry Value
NCT IdentifierNCT05798663
Consolidated Lead SponsorAlliance Foundation Trials
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment178 participants (ESTIMATED)
Registered Start Date2023-12-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05798663
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
Rush University Medical CenterChicago, ILOpen Hospital Dossier ->
Washington University and Siteman Cancer CenterSaint Louis, MOOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI